Developing a promising new cancer therapy based on natural killer cells
byAlbert Einstein College of MedicineLeft shows the tumor-cell protein PVR binding with the NK-cell receptor KIR2DL5 to prevent NK-cell attack. Right, monoclonal antibody short-circuits tumor ce
Updated on: December 26,2023
Developing a promising new cancer therapy based on natural killer cells
byAlbert Einstein College of MedicineLeft shows the tumor-cell protein PVR binding with the NK-cell receptor KIR2DL5 to prevent NK-cell attack. Right, monoclonal antibody short-circuits tumor ce
Updated on:December 26,2023
